Anika Therapeutics (ANIK) Depreciation and Depletion (2024 - 2026)

Anika Therapeutics (ANIK) has 3 years of Depreciation and Depletion data on file, last reported at $1.4 million in Q1 2026.

• On a quarterly basis, Depreciation and Depletion rose 16.67% year-over-year to $1.4 million in Q1 2026; TTM through Mar 2026 was $5.5 million, a 12.24% increase from a year earlier, with the FY2025 full-year figure at $5.4 million, up 8.0% from the prior year.
• Depreciation and Depletion for Q1 2026 stood at $1.4 million, roughly flat from $1.4 million in the prior quarter.
• Over the last five years, Depreciation and Depletion for ANIK reached as high as $1.4 million in Q3 2025 and fell as low as $1.2 million in Q1 2024.
• Historically, Depreciation and Depletion has averaged $1.3 million across 3 years, with a median of $1.3 million in 2024.
• On a YoY basis, Depreciation and Depletion climbed as much as 16.67% in 2025 and fell as far as 0.0% in 2025.
• Year by year, Depreciation and Depletion stood at $1.2 million in 2024, then advanced by 16.67% to $1.4 million in 2025, then changed by 0.0% to $1.4 million in 2026.
• Per Business Quant data, the three most recent Depreciation and Depletion figures were $1.4 million in Q1 2026, $1.4 million in Q4 2025, and $1.4 million in Q3 2025.